Trodusquemine (Genaera Corporation) and PTP1B antisense oligonucleotides (ISIS Pharmaceuticals) are currently in phase II clinical trials as a potential treatment for obesity and diabetes (58, 120). The gene discussed is PTPN1; the disease is obesity due to melanocortin 4 receptor deficiency.